Superworth

BIO-TECHNE price to book ratio TECH

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
5.4×
10-year median
5.9×
Against its 10-year history
34th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.3× to 13.5×
Peer median
6.3×

BIO-TECHNE's price to book ratio is 5.4× as of Oct 23, 2026.

That is below its ten-year median of 5.9×, lower than on 66% of days in the last ten years.

Over that time it ranged from 3.3× in May 2026 to 13.5× in Sep 2021.

The median for 10 biotech stocks of a similar size is 6.3×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.4×3.3×5.4×
20254.7×3.6×5.7×
20245.4×5.0×6.6×
20236.1×4.6×7.4×
20227.4×6.5×10.3×
202112.4×8.7×13.5×
20208.5×4.8×8.6×
20197.1×4.9×7.2×
20184.8×4.7×7.1×
20175.1×4.1×5.2×
20164.3×3.7×5.0×
20154.0×3.9×5.0×
20144.4×4.1×4.8×
20134.8×3.4×4.8×
20123.7×3.7×4.4×
20114.3×3.9×5.5×
20104.7×4.3×4.8×

Against its peers

Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.

CompanyPrice to book ratio
TECHBIO-TECHNE5.4×
RGENRepligen4.7×
KRYSKrystal Biotech6.8×
HALOHalozyme Therapeutics99.3×
NBIXNeurocrine Biosciences3.9×
EXELExelixis8.7×
INCYIncyte3.7×
UTHRUnited Therapeutics3.9×
ALNYAlnylam Pharmaceuticals22.1×
ONCBeOne Medicines8.3×
ADMAAdma Biologics5.9×
Peer median6.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on BIO-TECHNE

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.